Core Insights - The China International Import Expo (CIIE) serves as a crucial platform for global medical technology, showcasing cutting-edge innovations and attracting significant investment in China's healthcare sector [1][5] Group 1: Innovations and Product Launches - Sanofi showcased ten innovative products, including the global debut of cardiovascular drugs, highlighting advancements in targeted therapies for hypertrophic cardiomyopathy [2] - Fosun Pharma presented multiple leading global innovations, including the Marie particle therapy system, which significantly reduces the space and cost of traditional treatment rooms [2] - Abbott introduced over ten debut products, featuring advanced biowearable sensor technology and personalized diagnostic solutions [2] Group 2: Accelerated Approval and Market Entry - The "CIIE Baby" concept illustrates the rapid approval and market entry of innovative medical products in China, with Sanofi's Dupilumab injection exemplifying this trend by evolving through multiple indications over seven years [4][5] - Pfizer displayed 17 "CIIE Babies," emphasizing their commitment to accelerating innovation in China, with a goal of obtaining approvals for 60 innovative drugs and new indications by 2030 [6] Group 3: Investment and Local Production - Roche announced a new biopharmaceutical production base in China with an investment of 2.04 billion yuan, marking a significant step in their localization strategy [7] - Intuitive Surgical's partnership with Fosun Pharma for the Da Vinci surgical robot highlights the trend of exhibitors transitioning to investors, with a new facility in Shanghai set to enhance local production capabilities [9] Group 4: Ecosystem Development and Collaboration - The CIIE fosters collaboration among global pharmaceutical companies, with Sanofi and local biotech firms signing strategic agreements to deepen cooperation in drug development [8] - The event has become a magnet for innovation, with 60% of GE Healthcare's new products being led by Chinese teams, showcasing the growing role of local talent in global healthcare advancements [8]

Core Insights - Sanofi's Dupilumab injection (Dupixent®) has evolved significantly over seven years, expanding its indications and demonstrating the rapid pace of innovation in China [1][3][4] Group 1: Product Evolution - Dupilumab has transitioned from being recognized primarily for atopic dermatitis to covering seven indications, including respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) [3][4] - The drug's approval timeline in China has been notably faster than in the US and EU, showcasing "China speed" in regulatory processes [3] Group 2: Market Engagement - Sanofi has participated in the China International Import Expo (CIIE) for seven consecutive years, using the platform to enhance disease awareness and educate both the public and healthcare professionals [2][5] - The company has established a comprehensive value chain in China, including R&D, manufacturing, and commercial operations, reflecting its long-term commitment to the market [4] Group 3: Strategic Partnerships - Sanofi has formed significant collaborations with local partners, such as Shanghai Pharmaceuticals and KKR, to strengthen the pharmaceutical ecosystem in China [4] - The establishment of the Sanofi-KKR Innovation Fund, with a scale of approximately 2 billion yuan, aims to invest in innovative drug pipelines that have entered clinical stages in China [4]

Group 1 - Yara International's chairman was arrested for embezzlement and abuse of power, but the company's operations remain normal and control has not changed [2][9] - Tenglong Co., Ltd. reported that it has small-scale products indirectly applied in data center/server liquid cooling and energy storage liquid cooling, with limited revenue impact [3] - Xianda Co., Ltd. achieved a net profit of 136 million yuan in the first half of 2025, a year-on-year increase of 2561.58%, driven by rising product prices and new product launches [4][25] Group 2 - Jifeng Technology announced a collective resignation of its board members, leading to a change in control [5] - Xiling Information's controlling shareholder is under investigation, but the company's control remains unchanged [6] - Chitianhua's subsidiary plans a scheduled maintenance shutdown for 35 days, which will not affect annual production targets [7] Group 3 - Shentong Express reported a revenue of 4.287 billion yuan in July 2025, a year-on-year increase of 9.95% [8] - Tianyu Digital's board member was arrested for embezzlement, but the company maintains normal operations [9] - Shaanxi Natural Gas's controlling shareholder plans to transfer 13% of its shares, affecting the ownership structure [9] Group 4 - Kesheng Technology's actual controller is under investigation, but the company's operations remain normal [10] - Dazhu CNC reported a net profit of 263 million yuan in the first half of 2025, a year-on-year increase of 83.82% [11] - Jinli Permanent Magnet's net profit increased by 155% year-on-year, with significant sales in the new energy vehicle sector [12] Group 5 - China Shenhua's expansion project for the Wanzhou power plant has been approved with a total investment of 6.655 billion yuan [13] - Wanfu Biology reported a net profit of 189 million yuan in the first half of 2025, a year-on-year decrease of 46.82% [13] - Round Express reported a revenue increase of 12.08% in July 2025 [13] Group 6 - Soft Control Co., Ltd. reported a net profit decrease of 23.84% in the first half of 2025 [21] - Jiangte Electric's subsidiary has completed maintenance and will resume production [21] - Blue Ocean Huaten reported a net profit increase of 159.83% in the first half of 2025 [22]

Core Viewpoint - The company XinNuoWei announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, which will commence shortly [1] Group 1 - The approval pertains to the clinical trial notification for Dupilumab injection [1] - The clinical trials are expected to begin in the near future [1]

Core Viewpoint - The announcement by XinNuoWei regarding the approval of clinical trials for Dupilumab injection marks a significant step in the development of a biosimilar drug targeting IL-4Rα for the treatment of moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for Dupilumab injection [1] - Dupilumab injection is a fully human monoclonal antibody drug and is classified as a biosimilar to Dupixent [1] Industry Summary - The drug is categorized under biological products for therapeutic use, specifically as a Class 3.3 application, indicating its relevance in the biopharmaceutical sector [1] - The indication for Dupilumab injection is aimed at treating adults with moderate to severe atopic dermatitis, highlighting the growing demand for effective treatments in this therapeutic area [1]

Core Viewpoint - The announcement indicates that CSPC Pharmaceutical Group Limited has received approval from the National Medical Products Administration of China to conduct clinical trials for Dupilumab Injection, a monoclonal antibody drug targeting IL-4Rα, which is a biosimilar to Dupixent [1] Group 1: Product Development - The product is a recombinant fully human monoclonal antibody drug designed for the treatment of moderate to severe atopic dermatitis in adults [1] - The development of the product follows the relevant research guidelines for biosimilars, ensuring compliance with regulatory standards [1] Group 2: Research Findings - Pharmaceutical and non-clinical research results demonstrate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting the initiation of subsequent clinical studies [1]

Core Viewpoint - The announcement indicates that CSPC Pharmaceutical Group (01093.HK) has received approval from the National Medical Products Administration of China to conduct clinical trials for Dupilumab Injection, a biosimilar to Dupixent, targeting moderate to severe atopic dermatitis in adults [1] Group 1: Product Development - The product is a recombinant fully human monoclonal antibody drug targeting IL-4Rα, classified as a biosimilar to Dupixent [1] - The application was submitted under the category of biological products for therapeutic use, specifically Class 3.3 [1] - The research results from pharmaceutical and non-clinical studies demonstrate high similarity in quality, safety, and efficacy compared to the reference drug, supporting the initiation of subsequent clinical studies [1]

Group 1 - The core point of the article is that CSPC Pharmaceutical Group (01093) has received approval from the National Medical Products Administration of China to conduct clinical trials for its drug Dupilumab Injection [1] - The product is a recombinant fully human monoclonal antibody targeting IL-4Rα and is a biosimilar to Dupixent, classified under Category 3.3 for therapeutic biological products [1] - The drug is intended for the treatment of moderate to severe atopic dermatitis in adults [1] Group 2 - The development of the product follows the relevant research guidelines for biosimilars [1] - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting the initiation of subsequent clinical studies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的度普利尤單抗注射液（「該產品」）已獲中華人民共和國國家藥品監督管理 局批准，可在中國開展臨床試驗。 該產品是一種靶向IL -4Rα的重組全人源單克隆抗體藥物，為達必妥®的生物類似藥，按照 治療用生物製品3.3類申報，適用於治療成人中重度特應性皮炎。 該產品的研發遵循生物類似藥相關研究指南。藥學及非臨床研究結果顯示，該產品與原研 參照藥在質量、安全性和有效性方面高度相似，支持開展後續臨床研究。 代表董事會 石藥集團有限公司 主席 蔡東晨 香港，2025年8月19日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 ...

Core Viewpoint - The company XinNuoWei has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a monoclonal antibody drug targeting IL-4Rα, which is a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Company Summary - XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has been authorized to conduct clinical trials for Dupilumab injection [1] - The drug is classified as a Class 3.3 biological product for therapeutic use [1] Industry Summary - Dupilumab injection is positioned as a biosimilar to Dupixent, indicating a competitive entry into the market for treatments of atopic dermatitis [1] - The approval for clinical trials reflects ongoing advancements in biopharmaceuticals targeting specific conditions such as atopic dermatitis [1]